Canagliflozin: A new option for managing diabetesLivingston, Molly PharmD; Clements, Jennifer N. PharmD, BCPS, CDE, BCACPJournal of the American Academy of Physician Assistants: September 2014 - Volume 27 - Issue 9 - p 47–50 doi: 10.1097/01.JAA.0000453247.76333.09 What's New in Diabetes Abstract Author Information Abstract ABSTRACT: Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic infections. Author Information At the time this article was written, Molly Livingston was a student in the doctor of pharmacy program at Presbyterian College School of Pharmacy in Clinton, S.C. Jennifer N. Clements is an associate professor in the Department of Pharmacy Practice at Presbyterian College School of Pharmacy. The authors have disclosed no potential conflicts of interest, financial or otherwise. Mark E. Archambault, DHSc, PA-C, department editor © 2014 American Academy of Physician Assistants.